Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study.

[1]  J. Coebergh,et al.  Trends in colorectal cancer in the south of the Netherlands 1975–2007: Rectal cancer survival levels with colon cancer survival , 2010, Acta oncologica.

[2]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[3]  A. Margeli,et al.  Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: associations with clinicopathological variables and patient survival. , 2009, The International journal of biological markers.

[4]  T. Kirchner,et al.  The impact of microRNAs on colorectal cancer , 2009, Virchows Archiv.

[5]  J. Horiot,et al.  Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  N. Brünner,et al.  TIMP‐1 expression in human colorectal cancer is associated with TGF‐B1, LOXL2, INHBA1, TNF‐AIP6 and TIMP‐2 transcript profiles , 2008, Molecular oncology.

[7]  Tomoyuki Kato,et al.  Negative Serum Carcinoembryonic Antigen has Insufficient Accuracy for Excluding Recurrence from Patients with Dukes C Colorectal Cancer: Analysis with Likelihood Ratio and Posttest Probability in a Follow-Up Study , 2008, Diseases of the colon and rectum.

[8]  M. Gonen,et al.  Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy , 2008, Diseases of the colon and rectum.

[9]  Mithat Gonen,et al.  Individualized prediction of colon cancer recurrence using a nomogram. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Brünner,et al.  Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment , 2008, Scandinavian journal of gastroenterology.

[11]  T. Yoshikawa,et al.  Impact of Plasma Tissue Inhibitor of Matrix Metalloproteinase-1 on Long-Term Survival in Patients with Colorectal Cancer , 2007, Oncology.

[12]  A. Krüger,et al.  Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. , 2007, Cancer research.

[13]  H. Nielsen,et al.  TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid , 2007, Clinical Cancer Research.

[14]  R. Labianca,et al.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. , 2007, Journal of the National Cancer Institute.

[15]  M. Duffy,et al.  Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. , 2007, European journal of cancer.

[16]  S. Rho,et al.  TIMP‐1 regulates cell proliferation by interacting with the ninth zinc finger domain of PLZF , 2007, Journal of cellular biochemistry.

[17]  H. Nielsen,et al.  Investigation of tissue inhibitor of metalloproteinases 1 in plasma from colorectal cancer patients and blood donors by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. , 2007, The International journal of biological markers.

[18]  H. Nielsen,et al.  Investigation of tissue inhibitor of metalloproteinases 1 in plasma from colorectal cancer patients and blood donors by surface-enhanced laser desorption/ionization time-of-flight mass spectrometryscopy. , 2007, The International journal of biological markers.

[19]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  F. Hara,et al.  Suppression effects of human recombinant tissue inhibitor of metalloproteinases-1(TIMP-1) on tumor proliferation using in vivo treatment model of well-differentiated colon cancer cell line, HT29. , 2006, Acta medica Okayama.

[22]  H. Nielsen,et al.  Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. , 2006, European journal of cancer.

[23]  F. Greene.  Staging of colon and rectal cancer: from endoscopy to molecular markers , 2006, Surgical Endoscopy And Other Interventional Techniques.

[24]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[25]  T. Wobbes,et al.  Plasma Levels of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-1 Correlate With Disease Stage and Survival in Colorectal Cancer Patients , 2005, Diseases of the colon and rectum.

[26]  H. Nielsen,et al.  Localization of tissue inhibitor of metalloproteinases 1 (TIMP‐1) in human colorectal adenoma and adenocarcinoma , 2005, International journal of cancer.

[27]  H. Nielsen,et al.  Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. , 2004, European journal of cancer.

[28]  P. Russell,et al.  Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer , 2003, Journal of surgical oncology.

[29]  H. Nielsen,et al.  High serum YKL‐40 level after surgery for colorectal carcinoma is related to short survival , 2002, Cancer.

[30]  I. Goldberg,et al.  Complex roles of tissue inhibitors of metalloproteinases in cancer , 2002, Oncogene.

[31]  W. Stetler-Stevenson,et al.  Increased expression of tissue inhibitor of metalloproteinases type 1 (TIMP‐1) in a more tumourigenic colon cancer cell line , 2000, The Journal of pathology.

[32]  H. Nielsen,et al.  High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  K. Choe,et al.  Prognostic Factors in 2230 Korean Colorectal Cancer Patients: Analysis of Consecutively Operated Cases , 1999, World Journal of Surgery.

[34]  H. Nielsen,et al.  Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer , 1999, British Journal of Cancer.

[35]  W. Stetler-Stevenson,et al.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. , 1998, The Journal of clinical investigation.

[36]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[37]  R. G. Hoffman,et al.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. , 1978, The New England journal of medicine.

[38]  大谷 裕.  Suppression effects of human recombinant tissue inhibitor of metalloproteinases-1 (TIMP-1) on tumor proliferation using in vivo treatment model of well-differentiated colon cancer cell line, HT29 , 2007 .

[39]  H. Nielsen,et al.  Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study. , 2004, European journal of cancer.

[40]  H. Nielsen,et al.  Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  J. Chmiel,et al.  The use of cancer registry data to study preoperative carcinoembryonic antigen level as an indicator of survival in colorectal cancer , 1989, CA: a cancer journal for clinicians.